Jennifer Stevens - 24 Nov 2025 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Reporting relationship: Chief Regulatory Officer
Issuer ticker: TLSI
Reported as of: 24 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Nov 2025, 15:43:38 UTC
Prior SEC filing: 21 May 2025
Next SEC filing: 20 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Mary Szela, Attorney-in-Fact

Key filing fact

Jennifer Stevens filed Form 4 for TriSalus Life Sciences, Inc. (TLSI) on 25 Nov 2025.

Key facts

This page summarizes Jennifer Stevens's Form 4 filing for TriSalus Life Sciences, Inc. (TLSI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Nov 2025, 15:43.

Change

Previous filing in this sequence was filed on 21 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001982621 Primary reporting owner

Stevens Jennifer

Relationship: Chief Regulatory Officer
Address: 6272 W. 91ST AVENUE, WESTMINSTER
Signature: /s/ Mary Szela, Attorney-in-Fact
Signature date: 25 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TLSI transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %: +64%
Price: $0.000000
Shares after: 127,640
Date: 24 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TLSI transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %: +45%
Price: $0.000000
Shares after: 323,782
Date: 24 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $5.55
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date.

Footnote F2

One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date.